GrayBug
Redwood City
About GrayBug
GrayBug is a pharmaceutical company that develops transformative medicines for ocular diseases. They also develop therapies for inflammatory diseases with unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $129.2M
- Funding stage: M&A
- Last round: Series C (Aug 2019)
- Ticker: nasdaq:GRAY
- Website: graybug.vision
- Phone: +1 650 487 2800
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/graybug-17178 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.